Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Metformin577 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A08318 | 32153507 | Front Endocrinol (Lausanne) | Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. | 2020 | Details |
| A08364 | 32143184 | EBioMedicine | Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes. | 2020 | Details |
| A08502 | 32083947 | Can J Physiol Pharmacol | Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. | 2020 | Details |
| A08683 | 32023702 | Zhonghua Gan Zang Bing Za Zhi | [Effect of metformin on mitochondrial pathway of apoptosis and oxidative stress in cell model of nonalcoholic fatty liver disease]. | 2020 | Details |
| A08689 | 32020874 | BMC Complement Med Ther | Zhenqing recipe attenuates non-alcoholic fatty liver disease by regulating the SIK1/CRTC2 signaling in experimental diabetic rats. | 2020 | Details |
| A08856 | 31963648 | J Clin Med | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | 2020 | Details |
| A08871 | 31955626 | Endocr Res | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | 2020 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A09047 | 31889754 | J Clin Exp Hepatol | Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09337 | 31786336 | Biochim Biophys Acta Mol Basis Dis | Protective effect of metformin against palmitate-induced hepatic cell death. | 2019 | Details |
| A09343 | 31783920 | Syst Rev | Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. | 2019 | Details |
| A09381 | 31769484 | Clin Sci (Lond) | Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. | 2019 | Details |
| A09415 | 31757735 | Presse Med | [Pharmacological treatment of NASH]. | 2019 | Details |
| A09439 | 31749893 | Diabetol Metab Syndr | Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats. | 2019 | Details |
| A09569 | 31692226 | Diabetes Obes Metab | Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. | 2019 | Details |
| A09583 | 31686884 | Diabetes Metab Syndr Obes | Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. | 2019 | Details |
| A09734 | 31632109 | Diabetes Metab Syndr Obes | Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model. | 2019 | Details |
| A09758 | 31622581 | Am J Med | Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09912 | 31563650 | Eur J Pharmacol | Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. | 2019 | Details |
| A10051 | 31512431 | Adv Gerontol | [The effect of high-dose metformin on the metabolic parameters and functional state of the liver of agouti-mice with the melanocortin obesity.] | 2019 | Details |
| A10168 | 31460584 | Arq Gastroenterol | N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. | 2019 | Details |
| A10171 | 31455870 | Int J Obes (Lond) | Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes. | 2019 | Details |
| A10448 | 31333877 | Clin Diabetes Endocrinol | Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. | 2019 | Details |
| A10550 | 31292843 | Clin J Gastroenterol | Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. | 2019 | Details |
| A10850 | 31157422 | Aliment Pharmacol Ther | Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. | 2019 | Details |
| A10918 | 31124886 | J Pediatr Gastroenterol Nutr | Psychotropic Medications Are Associated With Increased Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A11018 | 31080822 | Biomed Res Int | Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. | 2019 | Details |
| A11105 | 31040374 | Sci Rep | Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. | 2019 | Details |
| A11165 | 31013454 | Metab Syndr Relat Disord | In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. | 2019 | Details |
| A11204 | 31000862 | J Pak Med Assoc | Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. | 2019 | Details |
| A11250 | 30973968 | Br J Clin Pharmacol | Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. | 2019 | Details |
| A11331 | 30935688 | Biochem Biophys Res Commun | Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo. | 2019 | Details |
| A11350 | 30927369 | Br J Pharmacol | Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. | 2019 | Details |
| A11365 | 30920975 | Eur J Gastroenterol Hepatol | Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. | 2019 | Details |
| A11392 | 30915409 | Clin Exp Hepatol | Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructose-induced fatty liver in rats. | 2019 | Details |
| A11476 | 30879942 | J Clin Lipidol | Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD? | 2019 | Details |
| A11714 | 30780126 | Pharmacol Rep | Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A11771 | 30757944 | Pharm Biol | Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. | 2019 | Details |
| A11803 | 30734333 | Hepatology | Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2019 | Details |
| A11810 | 30729549 | Hepatology | Reply. | 2019 | Details |
| A11919 | 30682184 | PLoS One | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. | 2019 | Details |
| A11969 | 30663219 | Liver Int | Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. | 2019 | Details |
| A11972 | 30661330 | J Exerc Nutrition Biochem | Hepatoprotective and anti-obesity effects of Korean blue honeysuckle extracts in high fat diet-fed mice. | 2018 | Details |
| A12000 | 30652641 | Curr Pharm Des | Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. | 2018 | Details |
| A12039 | 30628769 | ACS Appl Mater Interfaces | Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12184 | 30572006 | J Hepatol | Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. | 2018 | Details |
| A12365 | 30483596 | JGH Open | Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. | 2018 | Details |
| A12386 | 30473540 | Biosci Rep | Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. | 2018 | Details |
| A12407 | 30467936 | Pediatr Diabetes | Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects. | 2018 | Details |
| A12434 | 30456918 | Diabetes Obes Metab | Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? | 2018 | Details |
| A12499 | 30420265 | Arab J Gastroenterol | Managing diabetes and liver disease association. | 2018 | Details |
| A12514 | 30413050 | Pharmaceuticals (Basel) | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? | 2018 | Details |
| A12659 | 30341767 | Hepatology | Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12783 | 30288767 | Aliment Pharmacol Ther | Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. | 2018 | Details |
| A12801 | 30282916 | Diseases | Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. | 2018 | Details |
| A12863 | 30250238 | Sci Rep | Human hepatic 3D spheroids as a model for steatosis and insulin resistance. | 2018 | Details |
| A12888 | 30241400 | Int J Mol Sci | Metformin: An Old Drug with New Applications. | 2018 | Details |
| A12911 | 30229578 | Endocrinol Metab (Seoul) | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease. | 2018 | Details |
| A12922 | 30226474 | J Clin Invest | Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. | 2018 | Details |
| A12929 | 30221732 | Mol Med Rep | Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. | 2018 | Details |
| A12964 | 30206377 | Sci Rep | Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. | 2018 | Details |
| A13132 | 30122876 | World J Gastroenterol | Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. | 2018 | Details |
| A13139 | 30120555 | Pflugers Arch | Catalase and nonalcoholic fatty liver disease. | 2018 | Details |
| A13179 | 33435021 | ACS Biomater Sci Eng | Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. | 2018 | Details |
| A13467 | 29957886 | J Diabetes Investig | Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. | 2018 | Details |
| A13643 | 29858843 | Hormones (Athens) | The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). | 2018 | Details |
| A13785 | 29759071 | Lipids Health Dis | Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression. | 2018 | Details |
| A13822 | 29740791 | Paediatr Drugs | Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. | 2018 | Details |
| A13849 | 29728363 | Diabetes | Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. | 2018 | Details |
| A13915 | 29696666 | Aliment Pharmacol Ther | Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A13933 | 29682571 | Biomed Res Int | The Association of Gut Microbiota with Nonalcoholic Steatohepatitis in Thais. | 2018 | Details |
| A13962 | 29670844 | Adv Pharm Bull | The Eeffect of Metformin Combined with Calcium-Vitamin D3 Against Diet-Induced Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14003 | 29643297 | J Vet Med Sci | Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model. | 2018 | Details |
| A14125 | 29572891 | Hepatology | Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. | 2018 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14291 | 29480487 | Methods Mol Biol | Measurement of AMPK-Induced Inhibition of Lipid Synthesis Flux in Cultured Cells. | 2018 | Details |
| A14322 | 29466788 | Cell Physiol Biochem | Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice. | 2018 | Details |
| A14356 | 29450671 | Inflammopharmacology | Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. | 2018 | Details |
| A14358 | 29450137 | Biochim Open | Liver and Metformin: Lessons of a fructose diet in mice. | 2017 | Details |
| A14537 | 29363914 | Pol J Pathol | Expression of resistin in the liver of patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A14576 | 29344336 | Ther Adv Endocrinol Metab | Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. | 2017 | Details |
| A14577 | 29343420 | EBioMedicine | AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development. | 2018 | Details |
| A14639 | 29312569 | Oncotarget | Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway. | 2017 | Details |
| A14791 | 29231919 | Pol Merkur Lekarski | [Non-alcoholic liver disease - diagnosis and treatment]. | 2017 | Details |
| A14849 | 29204141 | Front Microbiol | Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. | 2017 | Details |
| A14893 | 29188065 | BMJ Open Diabetes Res Care | High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study. | 2017 | Details |
| A14968 | 29151501 | Intern Med | The Efficacy of Corticosteroid Therapy in a Patient with Non-alcoholic Steatohepatitis Overlapping Autoimmune Hepatitis. | 2017 | Details |
| A15101 | 29095942 | PLoS One | Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. | 2017 | Details |
| A15289 | 28985579 | Eur J Cancer | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. | 2017 | Details |
| A15358 | 28947922 | Clin Epigenetics | Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver. | 2017 | Details |
| A15467 | 28892924 | J Clin Diagn Res | Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats. | 2017 | Details |
| A15588 | 28825992 | J Nutr Biochem | Effects of delta-tocotrienol on obesity-related adipocyte hypertrophy, inflammation and hepatic steatosis in high-fat-fed mice. | 2017 | Details |
| A15694 | 28758096 | Ann Transl Med | Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. | 2017 | Details |
| A15768 | 28719078 | Diabetes Obes Metab | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. | 2017 | Details |
| A15798 | 28705172 | BMC Endocr Disord | Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | 2017 | Details |
| A15820 | 28694246 | Eur J Endocrinol | MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. | 2017 | Details |
| A15875 | 28676020 | Curr Vasc Pharmacol | Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. | 2018 | Details |
| A15912 | 28655690 | Pak J Pharm Sci | Metformin HCl has curative effect on rebuilding of ventricular diastolic functions in high-fat-diet fed rats. | 2017 | Details |
| A16016 | 28611274 | Ann Hepatol | Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. | 2018 | Details |
| A16080 | 28580278 | Mol Metab | FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis. | 2017 | Details |